01—Abstract
Summary
Summary of the 10-Q filed August 6, 2020. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc.'s (MRNA) Q2 2020 10-Q filing highlights a significant cash position of $3.07 billiona as of June 30, 2020, which the company believes is sufficient to fund operations for at least the next 12 months.
The company is heavily focused on the development of its mRNA-1273 vaccine candidate for COVID-19, which has advanced to Phase 3 clinical trials and is supported by substantial government funding, including a commitment from BARDA. However, the report also underscores numerous risks, particularly the ongoing COVID-19 pandemic, which has disrupted clinical trials and manufacturing. Moderna acknowledges the considerable financial and operational resources being diverted to the mRNA-1273 program, potentially impacting other development efforts.
The company emphasizes the novelty of mRNA therapeutics, noting that no mRNA drug has yet been approved, and highlights the inherent uncertainties and risks associated with clinical development, regulatory approval, and manufacturing at scale for this new class of medicines. Significant losses are anticipated to continue for the foreseeable future.
02—Key points
Key Highlights
- As of June 30, 2020, Moderna held approximately $3.07 billion in cash, cash equivalents, and investments, which is expected to fund operations for at least the next 12 months.
- The company is advancing its mRNA-1273 vaccine candidate for COVID-19 into Phase 3 clinical trials, supported by significant government funding.
- The COVID-19 pandemic has caused delays and interruptions in clinical trials and manufacturing operations, posing ongoing risks.
- Moderna continues to incur significant losses and anticipates further losses for the foreseeable future due to substantial investments in research and development.
- The company acknowledges the novelty and inherent risks of developing mRNA-based medicines, as no such drug has yet been approved by regulatory bodies.
- Management has implemented a voluntary trading restriction for executives and board members concerning mRNA-1273 related stock sales until a BLA filing or program discontinuation.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2020filed August 6, 2020Financial Statements
Q2 FY2020 against Q2 FY2019
| Line item | Q2 FY2020Q2 FY2019 | Change |
|---|---|---|
| Revenue | $67.00M$13.08M | +412.1% |
| Cost of Revenue | $0— | — |
| Gross Profit | $67.00M— | — |
| R&D Expenses | $152.00M$128.31M | +18.5% |
| Operating Expenses | $189.00M$156.79M | +20.5% |
| Operating Income | -$122.00M-$143.71M | +15.1% |
| Net Income | -$117.00M-$134.94M | +13.3% |
| EPS (Basic) | $-0.31$-0.41 | +24.4% |
| EPS (Diluted) | $-0.31— | — |
| Shares Outstanding (Basic) | 381.00M329.18M | +15.7% |
| Shares Outstanding (Diluted) | 381.00M— | — |
05—Questions
Frequently Asked Questions
How is Moderna's financial position as of June 30, 2020?
As of June 30, 2020, Moderna reported approximately $3.07 billion in cash, cash equivalents, and investments. The company believes this amount is sufficient to fund its projected operations through at least the next 12 months.
What is the status of Moderna's COVID-19 vaccine candidate, mRNA-1273?
Moderna's mRNA-1273 vaccine candidate for COVID-19 has advanced to Phase 3 clinical trials. The company is dedicating significant resources to its development and manufacturing, with substantial funding and support from government entities like BARDA.
What are the primary risks highlighted in this filing?
Key risks highlighted include the ongoing impact of the COVID-19 pandemic on clinical trials and manufacturing, the inherent uncertainties and development risks associated with novel mRNA therapeutics (as no mRNA drug has yet been approved), potential delays in regulatory approval, challenges in scaling up manufacturing, and the continued incurrence of significant operating losses. The company also notes the possibility of increased expenses and the need for additional capital.
How does Moderna plan to fund future operations if needed?
Moderna expects to finance future cash needs through a combination of public or private equity offerings, structured financings, debt financings, government funding arrangements, potential future strategic alliances, and marketing, manufacturing, distribution, and licensing arrangements.
06—Continue